Yao Wang
Education
M.P.H., epidemiology, Tulane University School of Public Health and Tropical Medicine; B.A., economics, Anhui University of Technology
Summary of Experience
Ms. Wang specializes in health economics and outcomes research (HEOR), with a particular focus on real-world evidence (RWE) generation. She has designed and conducted research to evaluate and compare the clinical, economic, and humanistic impacts of diseases and treatments across a variety of therapeutic areas, including hematology, oncology, rheumatology, dermatology, and cardiology. Her work has covered many different study types, including surveys, chart reviews, qualitative interviews, discrete-choice experiments (DCE), analyses of real-world databases, systematic literature reviews, and indirect comparisons. Ms. Wang’s work has been published in peer-reviewed journals and presented at clinical and economic research conferences.
-
Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer
The Prostate, 2024
2024Swami U, Xie B, Young C, Ramaswamy K, El-Chaar N, Gao W, Yang H, Wang Y, Mucha L
-
Real-World Incidence of Adverse Clinical Outcomes Among People With Coronary Artery Disease and/or Peripheral Artery Disease in Relation to Vascular Risk in the United States
The American Journal of Cardiology, 2023
2023Desai U, Babcock A, Wang Y, Akbarnejad H, Wirtz EL, Laliberte F, Lefebvre P, Kharat A
-
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review
Current Medical Research and Opinion, 2021
2021Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba C, Wang Y, King S, Levinson W, Guérin A, Lefebvre P, Davis LL
-
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study
Frontiers in Medicine, 2021
2021Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Hongbo Yang H, Moritz ML
-
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Journal of Blood Medicine, 2019
2019Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R